Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years ...

“Vaping can decrease saliva production, resulting in dry mouth and throat, which raises the risk of cavities, gum disease, ...

A long-running partnership between digital therapeutics (DTx ... as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief from other therapies.

Tralokinumab is approved for the treatment of adults with moderate-to-severe atopic dermatitis in the EU ... Earlier in the year, the Digital Medicine Society (DiME) released a new set of open ...

Rezpegaldesleukin is currently being investigated in the phase 2b REZOLVE-AD study (ClinicalTrials.gov Identifier: NCT06136741) in 398 adult patients with moderate to severe atopic dermatitis who ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

If your itching is severe and prevents you from sleeping at night, a doctor may also recommend an antihistamine. This can be used short term to help you sleep. However, it’s not a treatment for ...

Rezpegaldesleukin (Rezpeg; Nektar Therapeutics) has been granted fast track designation by the FDA for the treatment of adult and pediatric patients aged 12 years and older with moderate-to-severe ...

“Rezpegaldesleukin has the potential to address a significant unmet need for the millions of patients living with moderate-to-severe atopic dermatitis. We remain on track to announce topline data from ...